Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Pollitt

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Haematologica|July 21, 2018
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VIPhillip L R Nicolson, Craig E Hughes, Stephanie Watson, et al.
Journal of Thrombosis and Haemostasis : JTH|November 5, 2019
Interspecies differences in protein expression do not impact the spatiotemporal regulation of glycoprotein VI mediated activationJoanne L Dunster, Amanda J Unsworth, Alexander P Bye, et al.
The Journal of Experimental Medicine|February 4, 2015
Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activatorsUlrike Flierl, Tracy L Nero, Bock Lim, et al.
Communications Biology|April 7, 2023
Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonistsJoanne C Clark, Eleyna M Martin, Luis A Morán, et al.
Blood|December 22, 2011
CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for developmentBrenda A Finney, Edina Schweighoffer, Leyre Navarro-Núñez, et al.
Haematologica|January 18, 2020
Low-dose Btk inhibitors selectively block platelet activation by CLEC-2Phillip L R Nicolson, Sophie H Nock, Joshua Hinds, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Haematologica|July 21, 2018
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VIPhillip L R Nicolson, Craig E Hughes, Stephanie Watson, et al.
Journal of Thrombosis and Haemostasis : JTH|November 5, 2019
Interspecies differences in protein expression do not impact the spatiotemporal regulation of glycoprotein VI mediated activationJoanne L Dunster, Amanda J Unsworth, Alexander P Bye, et al.
The Journal of Experimental Medicine|February 4, 2015
Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activatorsUlrike Flierl, Tracy L Nero, Bock Lim, et al.
Communications Biology|April 7, 2023
Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonistsJoanne C Clark, Eleyna M Martin, Luis A Morán, et al.
Blood|December 22, 2011
CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for developmentBrenda A Finney, Edina Schweighoffer, Leyre Navarro-Núñez, et al.
Haematologica|January 18, 2020
Low-dose Btk inhibitors selectively block platelet activation by CLEC-2Phillip L R Nicolson, Sophie H Nock, Joshua Hinds, et al.
Pageof 4